Julie Gillespie

Led the sales strategy for Venclexta (oral ) and Gazyva (infusion) in Chronic Lymphocytic Leukemia (CLL) and Acute Myeloid Leukemia (AML), achieving 12.9% sales revenue growth, exceeding targets by 109.5%

• Utilized market analysis and competitive insights to refine sales strategies, optimizing targeting, positioning, and messaging
• To medical oncologist, hematologist, bone marrow transplant, infusion centers, pharmacy directors and KOL’s
• Collaborated with marketing, product development, and medical affairs to synchronize efforts and align sales objectives
• Drove awareness through digital marketing, using data analytics to boost product adoption in key accounts
• Cross-Functional Collaboration: Worked closely with marketing, medical affairs, regulatory, and commercial teams to ensure the successful launch and promotion of hematology treatments
• Consistently exceeded sales targets, contributing to growth in oncology market share
• Spearheaded the successful launch of Venclexta, resulting in significant product adoption

• Led the launch of Tymlos (injectable) securing formulary access across hospitals and specialty pharmacies
• Managed distribution and reimbursement strategies, ensuring optimal product availability
• Mentored and trained new sales reps, earning the “Bravo Award” for training excellence
• Exceeded sales goals, achieving 102% of YTD target in 2017 and consistently surpassing targets in subsequent years
• Recognized for leadership in training and management development, improving team performance 82% to 111% of annual sales plan within a 12-month period
• Supervised and managed team representatives by setting clear goals, providing training, and ensuring adherence to industry regulations and company policies
• Analyze sales data to track performance provided coaching, and optimized team resources to exceed sales goals by 35% while implementing strategies to drive revenue growth
• Fostered team collaboration, motivated individuals, and offered guidance to help them meet targets while supporting strong relationships with healthcare professionals and key stakeholders

• Drove market access and formulary approval for Novo Nordisk (injectable insulin) products, expanding market share through strategic contract negotiations
• Managed J-code reimbursement and buy-bill contracts to ensure reimbursement for diabetes therapies across healthcare networks
• Led sales strategy development, providing insights and mentoring junior reps
• Increased market share for Premier Health Network by 195%, making Novo Nordisk the preferred provider
• Ranked among the top 10% of sales reps for volume and market expansion

• Drove the adoption of Apligraf in hospitals, securing preferred formulary status across major hospital networks
• Conducted product education and clinical training to ensure stakeholders understood the benefits of Apligraf
• Executed sales strategies to ensure optimal product usage in hospital settings
• Exceeded sales targets, achieving 204% of sales goal, ranking 3rd out of 154 reps
• Secured formulary status for Apligraf in key hospital networks